Early-onset, progressive, frequent, extensive, and severe bone mineral and renal complications in multiple endocrine neoplasia type 1-associated primary hyperparathyroidism

Journal of Bone and Mineral Research

Volumn 25, Issue 11, 2010, Pages 2382-2391

  Lourenço Jr , Delmar M ^a   Coutinho, Flavia L ^a   Toledo, Rodrigo A ^a   Montenegro, Fabio Lm ^a   Correia Deur, Joya Em ^a   Toledo, Sergio Pa ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

bone and renal disease; bone mineral density; MEN1; outcome; primary hyperparathyroidism

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; CALCIUM; PARATHYROID HORMONE; PROLACTIN;

ADULT; ARTICLE; BONE DEMINERALIZATION; BONE DENSITY; BONE DISEASE; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; COMORBIDITY; DISEASE CONTROL; DISEASE SEVERITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; GASTRINOMA; HIP; HUMAN; KIDNEY DISEASE; LUMBAR SPINE; MALE; MULTIPLE ENDOCRINE NEOPLASIA; ONSET AGE; PARATHYROID HORMONE BLOOD LEVEL; PRIMARY HYPERPARATHYROIDISM; PROLACTIN BLOOD LEVEL; PROLACTINOMA; RADIUS; TERTIARY HEALTH CARE; UROLITHIASIS;

ADULT; AGE OF ONSET; AGED; BONE DENSITY; BRAZIL; CALCIFICATION, PHYSIOLOGIC; DENSITOMETRY; FEMALE; FRACTURES, BONE; HUMANS; HYPERPARATHYROIDISM; KIDNEY DISEASES; MALE; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; PREVALENCE; YOUNG ADULT;

EID: 77958565798     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbmr.125     Document Type: Article

References (34)

1. Silverberg SJ, Bilezikian JP,. The diagnosis and management of asymptomatic primary hyperparathyroidism. Nat Clin Pract Endocrinol Metab. 2006; 2: 494 -503.
2. Mosekilde L,. Primary hyperparathyroidism and the skeleton. Clin Endocrinol. 2008; 69: 1 -19.
3. DeLellis RA, Mazzaglia P, Mangray S,. Primary hyperparathyroidism: a current perspective. Arch Pathol Lab Med. 2008; 132: 1251 -1262.
4. Marx SJ, Simonds WF, Agarwal SK, et al. Hyperparathyroidism in hereditary syndromes: special expression and special managements. J Bone Miner Res. 2002; 17: N37 -43.
5. Yip L, Ogilvie JB, Challinor SM, et al. Identification of multiple endocrine neoplasia type 1 in patients with apparent sporadic primary hyperparathyroidism. Surgery. 2008; 144: 1002-1006; discussion 1006 -1007.
6. Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001; 86: 5658 -5671.
7. Vergès B, Boureille F, Goudet P, et al. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab. 2002; 87: 457 -465.
8. Machens A, Schaaf L, Karges W, et al. Age-related penetrance of endocrine tumours in multiple endocrine neoplasia type 1 (MEN1): a multicentre study of 258 gene carriers. Clin Endocrinol (Oxf). 2007; 67: 613 -622.
9. Katai M, Sakurai A, Ikeo Y, Hashizume K,. Primary hyperparathyroidism in patients with multiple endocrine neoplasia type 1: comparison with sporadic parathyroid adenomas. Horm Metab Res. 2001; 33: 499 -503.
10. Goudet P, Cougard P, Vergès B, et al. Hyperparathyroidism in multiple endocrine neoplasia type I: surgical trends and results of a 256-patient series from Groupe D'etude des Néoplasies Endocriniennes Multiples Study Group. World J Surg. 2001; 25: 886 -890.
11. Carling T, Udelsman R,. Parathyroid surgery in familial hyperparathyroid disorders. J Intern Med. 2005; 257: 27 -37.
12. Tonelli F, Marcucci T, Fratini G, Tommasi MS, Falchetti A, Brandi ML,. Is total parathyroidectomy the treatment of choice for hyperparathyroidism in multiple endocrine neoplasia type 1? Ann Surg. 2007; 246: 1075 -1082.
13. Norton JA, Venzon DJ, Berna MJ, et al. Prospective study of surgery for primary hyperparathyroidism (HPT) in multiple endocrine neoplasia-type 1 and Zollinger-Ellison syndrome: long-term outcome of a more virulent form of HPT. Ann Surg. 2008; 247: 501 -510.
14. Burgess JR, David R, Greenaway TM, Parameswaran V, Shepherd JJ,. Osteoporosis in multiple endocrine neoplasia type 1: severity, clinical significance, relationship to primary hyperparathyroidism, and response to parathyroidectomy. Arch Surg. 1999; 134: 1119 -1123.
15. Lourenço DM Jr, Toledo RA, Mackowiak II, et al. Multiple endocrine neoplasia type 1 in Brazil: MEN1 founding mutation, clinical features, and bone mineral density profile. Eur J Endocrinol. 2008; 159: 259 -274.
16. Eller-Vainicher C, Chiodini I, Battista C, et al. Sporadic and MEN1-related primary hyperparathyroidism: differences in clinical expression and severity. J Bone Miner Res. 2009; 24: 1404 -1410.
17. Silverberg SJ, Shane E, de la Cruz L, et al. Skeletal disease in primary hyperparathyroidism. J Bone Miner Res. 1989; 4: 283 -291.
18. Parisien M, Silverberg SJ, Shane E, et al. The histomorphometry of bone in primary hyperparathyroidism: preservation of cancellous bone structure. J Clin Endocrinol Metab. 1990; 70: 930 -938.
19. Dempster DW, Müller R, Zhou H, et al. Preserved three-dimensional cancellous bone structure in mild primary hyperparathyroidism. Bone. 2007; 41: 19 -24.
20. Coutinho FL, Lourenço DM Jr, Toledo RA, Montenegro FL, Correia-Deur JE, Toledo SP,. Bone mineral density analysis in patients with primary hyperparathyroidism associated with multiple endocrine neoplasia type 1 after total parathyroidectomy. Clin Endocrinol (Oxf). 2010; 72: 462 -468.
21. Silverberg SJ, Gartenberg F, Jacobs TP, et al. Increased bone mineral density after parathyroidectomy in primary hyperparathyroidism. J Clin Endocrinol Metab. 1995; 80: 729 -734.
22. Silverberg SJ, Gartenberg F, Jacobs TP, et al. Longitudinal measurements of bone density and biochemical indices in untreated primary hyperparathyroidism. J Clin Endocrinol Metab. 1995; 80: 723 -728.
23. Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP,. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med. 1999; 341: 1249 -1255.
24. Rubin MR, Bilezikian JP, McMahon DJ, et al. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab. 2008; 93: 3462 -3470.
25. Silverberg SJ, Shane E, Jacobs TP, et al. Nephrolithiasis and bone involvement in primary hyperparathyroidism. Am J Med. 1990; 89: 327 -334.
26. Lamers CB, Froeling PG,. Clinical significance of hyperparathyroidism in familial multiple endocrine adenomatosis type I (MEA I). Am J Med. 1979; 66: 422 -424.
27. Christopoulos C, Antoniou N, Thempeyioti A, Calender A, Economopoulos P,. Familial multiple endocrine neoplasia type I: the urologist is first on the scene. BJU Int. 2005; 96: 884 -887.
28. Lourenço DM Jr, Toledo RA, Coutinho FL, et al. The impact of clinical and genetic screenings on the management of the multiple endocrine neoplasia type 1. Clinics (Sao Paulo). 2007; 62: 465 -476.
29. Toledo RA, Lourenco DM, Coutinho FL, et al. Novel MEN1 germline mutations in Brazilian families with multiple endocrine neoplasia type 1. Clin Endocrinol (Oxf). 2007; 67: 377 -384.
30. Lewiecki EM, Gordon CM, Baim S, et al. International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions. Bone. 2008; 43: 1115 -1121.
31. Bilezikian JP, Khan AA, Arnold A, et al. Third International Workshop on the Management of Asymptomatic Primary Hyperthyroidism Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab. 2009; 94: 335 -339.
32. Moosgaard B, Vestergaard P, Heickendorff L, Melsen F, Christiansen P, Mosekilde L,. Vitamin D status, seasonal variations, parathyroid adenoma weight and bone mineral density in primary hyperparathyroidism. Clin Endocrinol (Oxf). 2005; 63: 506 -513.
33. Kawamata A, Izu Y, Yokoyama H, et al. JunD suppresses bone formation and contributes to low bone mass induced by estrogen depletion. J Cell Biochem. 2008; 103: 1037 -1045.
34. Agarwal SK, Kennedy PA, Scacheri PC, et al. Menin molecular interactions: insights into normal functions and tumorigenesis. Horm Metab Res. 2005; 37: 369 -374.